<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03141658</url>
  </required_header>
  <id_info>
    <org_study_id>TS134-US103</org_study_id>
    <nct_id>NCT03141658</nct_id>
  </id_info>
  <brief_title>Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects</brief_title>
  <official_title>A Randomized, Single-blind, Parallel-group Study to Evaluate the Effects of TS-134 on Ketamine-induced BOLD Signals in Resting fMRI in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of TS-134 on ketamine-induced BOLD
      signals in ROIs in resting fMRI in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">April 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD fMRI signals in pre-specified ROIs</measure>
    <time_frame>Screening and Day 6</time_frame>
    <description>Changes in ketamine-induced BOLD fMRI signals in pre-specified ROIs (anterior cingulate cortex (ACC) and anterior insula) following administrations of TS-134</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BOLD fMRI signals in whole brain</measure>
    <time_frame>Screening and Day 6</time_frame>
    <description>Changes in ketamine-induced BOLD fMRI signals in whole brain following administrations of TS-134</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS)</measure>
    <time_frame>Screening and Day 6</time_frame>
    <description>Changes in BPRS scores following administrations of TS-134</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Administered Dissociative State Scale (CADSS)</measure>
    <time_frame>Screening and Day 6</time_frame>
    <description>Changes in CADSS scores following administrations of TS-134</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TS-134 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TS-134 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-134</intervention_name>
    <description>Multiple dose titrations from 10 mg to 20 mg once daily for 6 days</description>
    <arm_group_label>TS-134 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-134</intervention_name>
    <description>Multiple dose titrations from 10 mg to 60 mg once daily for 6 days</description>
    <arm_group_label>TS-134 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple doses of placebo once daily for 6 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6</description>
    <arm_group_label>TS-134 20 mg</arm_group_label>
    <arm_group_label>TS-134 60 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male and female subjects between 18 and 55 years of age inclusive (at
             the time of initial informed consent)

          -  Body weight ≥ 45 and ≤ 87 kg

          -  Body Mass Index (BMI) ≥ 18 and ≤ 30 kg/m2

        Exclusion Criteria:

          -  Female subjects who are pregnant, intend to become pregnant, or are breastfeeding

          -  History or presence of psychiatric or neurologic disease or condition

          -  History of first-degree relative with schizophrenia or mood disorder with psychosis

          -  History of alcohol or drug abuse

          -  History of recreational ketamine use, recreational PCP use, or an adverse reaction to
             ketamine

          -  History of violence

          -  Presence or positive history of significant medical illness, including high blood
             pressure, low blood pressure or orthostatic hypotension

          -  Any subjects who show subthreshold ketamine BOLD response

          -  Metal implants, pacemaker, other metal or paramagnetic objects contained within the
             body

          -  Claustrophobia

          -  Subject with any history of suicidal behavior or is currently at risk of suicide in
             the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A Lieberman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TS-134</keyword>
  <keyword>ketamine</keyword>
  <keyword>fMRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

